CytomX Therapeutics, Inc. (CTMX)
2.72
+0.03
(+1.12%)
USD |
NASDAQ |
Sep 16, 14:58
CytomX Therapeutics Enterprise Value : 260.66M for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 260.66M |
| September 14, 2026 | 371.78M |
| September 11, 2026 | 391.40M |
| September 10, 2026 | 404.47M |
| September 09, 2026 | 445.87M |
| September 08, 2026 | 469.84M |
| September 04, 2026 | 482.91M |
| September 03, 2026 | 476.38M |
| September 02, 2026 | 485.09M |
| September 01, 2026 | 474.20M |
| August 31, 2026 | 406.65M |
| August 28, 2026 | 373.96M |
| August 27, 2026 | 419.72M |
| August 26, 2026 | 397.93M |
| August 25, 2026 | 408.83M |
| August 24, 2026 | 391.40M |
| August 21, 2026 | 389.22M |
| August 20, 2026 | 391.40M |
| August 19, 2026 | 452.41M |
| August 18, 2026 | 413.19M |
| August 17, 2026 | 426.26M |
| August 14, 2026 | 406.65M |
| August 13, 2026 | 404.47M |
| August 12, 2026 | 434.98M |
| August 11, 2026 | 426.26M |
| Date | Value |
|---|---|
| August 10, 2026 | 424.08M |
| August 07, 2026 | 428.44M |
| August 06, 2026 | 408.83M |
| August 05, 2026 | 404.47M |
| August 04, 2026 | 397.93M |
| August 03, 2026 | 365.25M |
| July 31, 2026 | 349.99M |
| July 30, 2026 | 389.22M |
| July 29, 2026 | 365.25M |
| July 28, 2026 | 376.14M |
| July 27, 2026 | 382.68M |
| July 24, 2026 | 380.50M |
| July 23, 2026 | 400.11M |
| July 22, 2026 | 400.11M |
| July 21, 2026 | 419.72M |
| July 20, 2026 | 441.51M |
| July 17, 2026 | 463.30M |
| July 16, 2026 | 473.11M |
| July 15, 2026 | 476.38M |
| July 14, 2026 | 472.02M |
| July 13, 2026 | 480.73M |
| July 10, 2026 | 493.81M |
| July 09, 2026 | 536.30M |
| July 08, 2026 | 509.06M |
| July 07, 2026 | 511.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals, Inc. | 74.74B |
| ACADIA Pharmaceuticals, Inc. | 3.724B |
| Alnylam Pharmaceuticals, Inc. | 31.54B |
| Anika Therapeutics, Inc. | 266.68M |
| Savara, Inc. | 937.77M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.67M |
| Revenue (Quarterly) | 1.418M |
| Total Expenses (Quarterly) | 22.08M |
| EPS Diluted (Quarterly) | -0.0944 |
| Gross Profit Margin (Quarterly) | 96.69% |
| Profit Margin (Quarterly) | -1.46K% |
| Earnings Yield | -16.80% |
| Normalized Earnings Yield | -16.82 |